Does knowledge guide practice? Another look at the management of non-small-cell lung cancer.

PURPOSE To describe Canadian doctors' beliefs about the appropriate role of chemotherapy and radiotherapy in the management of non-small-cell lung cancer (NSCLC). METHODS A mail survey of a random sample of Canadian respirologists, thoracic surgeons, radiation oncologists, and medical oncologists was performed. Three cases of NSCLC were described and respondents were asked to estimate the prognosis in each case and to give their treatment recommendations. RESULTS Responses were obtained from 234 of 330 eligible subjects (74%). Doctors' treatment recommendations varied widely. After a complete resection for stage II NSCLC, 68% recommended no adjuvant treatment, 28% recommended radiotherapy, 1% recommended chemotherapy, and 3% recommended both radiotherapy and chemotherapy. For an asymptomatic patient with stage IIIb NSCLC, 17% recommended no active treatment, 65% recommended radiotherapy alone, 16% recommended radiation and chemotherapy, and 2% recommended chemotherapy alone. For an asymptomatic patient with a stage IV NSCLC, 80% recommended no active treatment and 20% recommended chemotherapy. Doctors' beliefs about the natural history of NSCLC and its response to treatment varied widely. Seventy-five percent of respondents believed that adjuvant radiotherapy did not increase survival in stage II disease, but 25% believed that it did. Thirty percent believed that the addition of chemotherapy to radiotherapy in stage III increased survival, but 70% believed that it did not. Fifty-five percent believed that chemotherapy increased the median survival in stage IV, but 45% believed that it did not. Doctors' beliefs about the efficacy of treatment were strongly associated with their treatment recommendations. CONCLUSION Personal beliefs, rather than universal knowledge, currently guide the management of NSCLC in Canada.

[1]  W. Mackillop,et al.  Variations in the management and outcome of non-small cell lung cancer in Ontario. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  P. Novotny,et al.  Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Oxman,et al.  Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[5]  David M. Eddy,et al.  A Manual for Assessing Health Practices & Designing Practice Policies: The Explicit Approach , 1992 .

[6]  M. Field,et al.  Guidelines for Clinical Practice: From Development to Use , 1992 .

[7]  A. Munro Decision analysis in oncology: panacea or chimera? , 1992, Clinical oncology (Royal College of Radiologists (Great Britain)).

[8]  F. Guidi,et al.  A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Propert,et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. , 1990, The New England journal of medicine.

[10]  B. O'Sullivan,et al.  Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  A M Epstein,et al.  The outcomes movement--will it get us where we want to go? , 1990, The New England journal of medicine.

[12]  G. Luporini,et al.  A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. , 1988, Seminars in oncology.

[13]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Moros The Philosophy of Medicine: Clinical Science and Its Ethics , 2015, Perspectives in biology and medicine.

[15]  B. O'Sullivan,et al.  The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. , 1986, British Journal of Cancer.

[16]  T. Shields,et al.  Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung , 1982, Cancer.

[17]  M Lavandier,et al.  Benefits of polychemotherapy in advanced non‐small‐cell bronchogenic carcinoma , 1982, Cancer.

[18]  C. Eastridge,et al.  Adjuvant cancer chemotherapy after resection of carcinoma of the lung , 1977, Cancer.